Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrence

Castellaneta, A and Massaro, A and Rendina, M and D'Errico, F and Carparelli, S and Rizzi, SF and Thomson, AW and Di Leo, A (2016) Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrence. Transplantation Research, 5 (1).

Published Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: Silibinin has been shown to have anti-HCV activity and immune-modulating properties by regulating dendritic cell (DC) function. DCs are antigen-presenting cells that, together with regulatory T cells (Treg), play a pivotal role in controlling alloimmune, as well as anti-HCV immune responses. Methods: Twelve liver transplant patients with HCV recurrence received iv infusion of Silibinin (iv-SIL) for 14 consecutive days. Using flow cytometry, before and at the end of treatment, we determined the frequencies of circulating myeloid (m) and plasmacytoid (p) DC and Treg and the expression of costimulatory/coregulatory molecules by the DC subsets and Treg. Statistical analysis was performed using the paired Student's t test and Pearson correlation test. Results: After iv-SIL treatment, we observed an elevated plasmacytoid dendritic cell (pDC)/myeloid dendritic cell (mDC) ratio, while pDC displayed lower HLA-DR and higher immunoglobulin-like transcript 4 (ILT4), CD39, and HLA-G expression compared to the pretreatment baseline. In addition, after iv-SIL, mDC showed increased inducible costimulator ligand (ICOSL) expression. No changes were detected in Treg frequency or programed death (PD)-1 expression by these cells. Moreover, several correlations between DC/Treg markers and clinical parameters were detected. Conclusions: This descriptive study, in liver transplant patients with HCV recurrence, reveals the impact of iv-SIL on DC and Treg. The changes observed in circulating pDC and mDC that have previously been associated with tolerogenic conditions shed new light on how iv-SIL may regulate anti-viral and alloimmunity. We have also observed multiple clinical correlations that could improve the clinical management of liver transplant patients and that deserve further analysis.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Castellaneta, A
Massaro, A
Rendina, M
D'Errico, F
Carparelli, S
Rizzi, SF
Thomson, AW
Di Leo, A
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 January 2016
Date Type: Publication
Journal or Publication Title: Transplantation Research
Volume: 5
Number: 1
DOI or Unique Handle: 10.1186/s13737-016-0030-7
Schools and Programs: School of Medicine > Surgery
Refereed: Yes
Date Deposited: 25 Jul 2016 17:49
Last Modified: 30 Mar 2021 10:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item